Neuland Laboratories Set to Launch New Peptide Facility This Summer

Officials at Neuland Laboratories announced that the company’s new commercial peptide facility is on track to begin operations this summer at its 17-acre manufacturing campus in Bonthapally, India. The facility aims to enhance Neuland’s capabilities in peptide production, with plans for further expansion as demand from clients continues to grow.

The first of four planned modules is expected to be operational by the summer of 2023, with an investment of approximately $30 million already secured for Module One. This module will provide significant production capacity, featuring 6,370 L of reactor capacity for both solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS). Specifically, it will accommodate reactor sizes ranging from 250 L to 3,000 L in LPPS and up to 500 L for SPPS.

The construction of this facility began last year, and it is designed to support client projects from small-scale developments to multi-ton commercial volumes. This versatility is particularly important for complex and long-chain peptide programs, as noted by a company spokesperson.

Saharsh Davuluri, vice chairman and managing director of Neuland, emphasized the site’s capacity for ongoing expansion: “The site has been designed for ongoing expansion, with space to accommodate additional SPPS synthesizers of 2,000 L and multiple 5,000 L LPPS reactors as future modules come online. This allows us to scale responsibly and in line with customer needs.”

In addition to expanding production capabilities, Neuland plans to increase its research and development staff at a double-digit rate in the coming year. The manufacturing team is also expected to more than double in size to support the ramp-up of operations at the new facility. This growth aligns with Neuland’s existing manufacturing capabilities, which currently include 1,174,000 L of active pharmaceutical ingredient (API) manufacturing capacity across three FDA-approved facilities. These facilities are complemented by a large, dedicated R&D center nearby, facilitating seamless scale-up and efficient development-to-commercial execution.

“This new facility marks our strategic entry into commercial-scale peptide manufacturing,” Davuluri stated. “A key part of our strategy will be to first support innovator and emerging biotech companies across all areas of novel peptide development, as well as the ongoing demand for GLP-1 manufacturing. We see commercial peptide production as a key growth driver for the business over the coming years.”

Neuland aims to roll out all modules of the new peptide facility in alignment with customer demand, reflecting its commitment to meet the needs of innovator and emerging biotech programs. As the global peptide market continues to evolve, Neuland’s strategic investments and expansions position it to play a significant role in addressing the growing demand for peptide therapies.